Antiproliferative effects of carbon monoxide on pancreatic cancer

Digestive and Liver Disease

Volumn 46, Issue 4, 2014, Pages 369-375

  Vítek, Libor ^a   Gbelcová, Helena ^b,e   Muchová, Lucie ^a   Váňová, Kateřina ^a   Zelenka, Jaroslav ^a,f   Koníčková, Renata ^a   Šuk, Jakub ^a   Zadinova, Marie ^a   Knejzlík, Zdeněk ^b   Ahmad, Shakil ^c,d   Fujisawa, Takeshi ^c   Ahmed, Asif ^c,d   Ruml, Tomáš ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d ASTON UNIVERSITY   (United Kingdom)

^e Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^f INSTITUTE OF PHYSIOLOGY   (Czech Republic)

Author keywords

Anticancer effects; Heme catabolic pathway; Heme oxygenase

Indexed keywords

CARBON MONOXIDE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CANCER TISSUE; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG TISSUE LEVEL; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; SURVIVAL RATE; TUMOR XENOGRAFT; XENOTRANSPLANTATION;

ANTICANCER EFFECTS; HEME CATABOLIC PATHWAY; HEME OXYGENASE;

ANIMALS; CARBON MONOXIDE; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; GASOTRANSMITTERS; HUMANS; MICE; MICE, NUDE; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895515837     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.12.007     Document Type: Article

References (36)

1. Dulak J., Deshane J., Jozkowicz A., et al. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation 2008, 117:231-241.
2. Wu L., Wang R. Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacological Reviews 2005, 57:585-630.
3. Jones M.K., Tsugawa K., Tarnawski A.S., et al. Dual actions of nitric oxide on angiogenesis: possible roles of PKC, ERK, and AP-1. Biochemical and Biophysical Research Communications 2004, 318:520-528.
4. Choi Y.K., Kim C.K., Lee H., et al. Carbon monoxide promotes VEGF expression by increasing HIF-1alpha protein level via two distinct mechanisms, translational activation and stabilization of HIF-1alpha protein. Journal of Biological Chemistry 2010, 285:32116-32125.
5. Abraham N.G., Jiang H., Balazy M., et al. Methods for measurements of heme oxygenase (HO) isoforms-mediated synthesis of carbon monoxide and HO-1 and HO-2 proteins. Methods in Molecular Medicine 2003, 86:399-411.
6. Motterlini R., Clark J.E., Foresti R., et al. Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. Circulation Research 2002, 90:E17-E24.
7. Motterlini R., Otterbein L.E. The therapeutic potential of carbon monoxide. Nature Reviews Drug Discovery 2010, 9:728-743.
8. Guo Y.R., Stein A.B., Wu W.J., et al. Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo. American Journal of Physiology Heart and Circulatory Physiology 2004, 286:H1649-H1653.
9. Ko A.H., Dito E., Schillinger B., et al. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable. Investigational New Drugs 2008, 26:463-471.
10. Parsons C.M., Muilenburg D., Bowles T.L., et al. The role of Akt activation in the response to chemotherapy in pancreatic cancer. Anticancer Research 2010, 30:3279-3289.
11. Schlieman M.G., Fahy B.N., Ramsamooj R., et al. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. British Journal of Cancer 2003, 89:2110-2115.
12. Fahy B.N., Schlieman M.G., Virudachalam S., et al. Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. Journal of the American College of Surgeons 2004, 198:591-599.
13. Fahy B.N., Schlieman M., Virudachalam S., et al. AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. British Journal of Cancer 2003, 89:391-397.
14. Gbelcova H., Lenicek M., Zelenka J., et al. Differences in antitumor effects of various statins on human pancreatic cancer. International Journal of Cancer 2008, 122:1214-1221.
15. McKeage M.J., Kelland L.R., Boxall F.E., et al. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo. Cancer Research 1994, 54:4118-4122.
16. Vreman H.J., Wong R.J., Kadotani T., et al. Determination of carbon monoxide (CO) in rodent tissue: effect of heme administration and environmental CO exposure. Analytical Biochemistry 2005, 341:280-289.
17. Vreman H.J., Kwong L.K., Stevenson D.K. Carbon monoxide in blood; an improved microliter blood-sample collection system, with rapid analysis by gas chromatography. Clinical Chemistry 1984, 30:1382-1386.
18. Bussolati B., Dunk C., Grohman M., et al. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. American Journal of Pathology 2001, 159:993-1008.
19. Ackah E., Yu J., Zoellner S., et al. Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. Journal of Clinical Investigation 2005, 115:2119-2127.
20. Ryter S.W., Alam J., Choi A.M. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiological Reviews 2006, 86:583-650.
21. Rose C.S., Jones R.A., Jenkins L.J., et al. The acute hyperbaric toxicity of carbon monoxide. Toxicology and Applied Pharmacology 1970, 17:752-760.
22. Olson K.R., Donald J.A., Dombkowski R.A., et al. Evolutionary and comparative aspects of nitric oxide, carbon monoxide and hydrogen sulfide. Respiratory Physiology and Neurobiology 2012, 184:117-129.
23. Fukumura D., Kashiwagi S., Jain R.K. The role of nitric oxide in tumour progression. Nature Reviews Cancer 2006, 6:521-534.
24. Ahmad S., Hewett P.W., Wang P., et al. Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circulation Research 2006, 99:715-722.
25. Murohara T., Asahara T., Silver M., et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. Journal of Clinical Investigation 1998, 101:2567-2578.
26. Dimmeler S., Assmus B., Hermann C., et al. Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis. Circulation Research 1998, 83:334-341.
27. Chen C.N., Hsieh F.J., Cheng Y.M., et al. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer. Journal of Surgical Oncology 2006, 94:226-233.
28. Ridnour L.A., Thomas D.D., Donzelli S., et al. The biphasic nature of nitric oxide responses in tumor biology. Antioxidants and Redox Signalling 2006, 8:1329-1337.
29. Becker J.C., Fukui H., Imai Y., et al. Colonic expression of heme oxygenase-1 is associated with a better long-term survival in patients with colorectal cancer. Scandinavian Journal of Gastroenterology 2007, 42:852-858.
30. Ferrando M., Gueron G., Elguero B., et al. Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer. Angiogenesis 2011, 14:467-479.
31. Allanson M., Reeve V.E. Carbon monoxide signalling reduces photocarcinogenesis in the hairless mouse. Cancer Immunology and Immunotherapy 2007, 56:1807-1815.
32. Zou C., Zhang H., Li Q., et al. Heme oxygenase-1: a molecular brake on hepatocellular carcinoma cell migration. Carcinogenesis 2011, 32:1840-1848.
33. Bergstraesser C., Hoeger S., Song H., et al. Inhibition of VCAM-1 expression in endothelial cells by CORM-3: the role of the ubiquitin-proteasome system, p38, and mitochondrial respiration. Free Radical Biology and Medicine 2012, 52:794-802.
34. Brune B., Ullrich V. Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase. Molecular Pharmacology 1987, 32:497-504.
35. Pilz R.B., Casteel D.E. Regulation of gene expression by cyclic GMP. Circulation Research 2003, 93:1034-1046.
36. Diez H., Garrido J.J., Wandosell F. Specific roles of Akt iso forms in apoptosis and axon growth regulation in neurons. PLoS One 2012, 7:e32715.